Surrozen, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals

In a preclinical model of pulmonary fibrosis, a surrozen antibody-based swap platform molecule decreased pulmonary inflammation and fibrosis and improved lung function surrozen wnt mimetic swap molecules also expanded alveolar organoid cultures and impacted multiple lung cell types in vivo results highlight the potential of wnt mimetic agonists to repair tissue after damage in severe lung diseases like idiopathic pulmonary fibrosis south san francisco, calif., april 03, 2024 (globe newswire) -- surrozen, inc. (nasdaq: srzn), a company pioneering targeted therapeutics that selectively modulate the wnt pathway for tissue repair and regeneration, announced today publication of data in respiratory research highlighting the potential for surrozen's wnt mimetic technologies to treat serious lung diseases like idiopathic pulmonary fibrosis (ipf) https://respiratory-research...

-   $17.5 million upfront proceeds with up to an additional $175 million of proceeds upon the exercise of warrants -   initial capital funds expansion of phase 1b trial in severe alcohol-associated hepatitis and extends cash runway -   phase ib data in expanded study expected in 1h 2025 south san francisco, calif., april 01, 2024 (globe newswire) -- surrozen, inc. (“surrozen” or the “company”) (nasdaq: srzn, srznw), a company pioneering targeted therapeutics that selectively activate the wnt pathway for tissue repair and regeneration, today announced that it has entered into securities purchase agreements with certain institutional and accredited investors to purchase shares of common stock, pre-funded warrants and accompanying warrants to purchase shares of common stock.

-phase 1a trial demonstrated acceptable safety and tolerability with no reported serious adverse events -phase 1a data demonstrated target engagement, a pharmacodynamic effect and effects on liver function -initiating phase 1b proof-of-concept trial in severe alcohol-associated hepatitis - expect to present safety, pd and pk data for szn-043 at upcoming medical meeting in 2024 south san francisco, calif., april 01, 2024 (globe newswire) -- surrozen, inc. (“surrozen” or the “company”) (nasdaq: srzn), a company pioneering targeted therapeutics that selectively activate the wnt pathway for tissue repair and regeneration, today provided an update on the phase 1a clinical trial of szn-043 in healthy volunteers and patients with cirrhosis.

Announces strategic prioritization of clinical programs to focus on development of szn-043 for alcohol-associated hepatitis szn-043- completed enrollment for the phase 1a clinical trial in chronic liver disease patients and healthy volunteers- expect to announce phase 1a safety and pharmacodynamic data in q1 2024- expect to initiate enrollment in the phase 1b clinical trial in patients with alcohol-associated hepatitis in 2024 and anticipate proof-of-concept data may be available in the second half of 2024 szn-1326 - company discontinues clinical development of szn-1326 in inflammatory bowel disease due to the challenges of identifying a safe and effective dose for further development and other strategic considerations $43...

Expect to announce data from szn-043 phase 1a clinical trial in patients with chronic liver disease and in healthy volunteers in q1 2024

Yet again, the Oracle of Omaha has bolstered his stake in a media giant's tracking stocks, even with shares in retreat.

Surrozen, Inc. (SRZN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

These top-ranked stocks are likely to beat on the bottom line in their next releases. Tap Lamb Weston (LW), NeoGenomics (NEO), Surrozen (SRZN), KE Hodlings (BEKE) and Insperity (NSP).

CELU, MGI, LRMR, EQRX and SRZN have been added to the Zacks Rank #1 (Strong Buy) List on April 12, 2023.

SOUTH SAN FRANCISCO, Calif., March 20, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), today announced that it will report fourth quarter and full year 2022 financial results and provide a corporate and pipeline progress report on Wednesday, March 22, 2023 after the close of the U.S. financial markets.   Company management will host a live audio webcast at 4:30 PM Eastern Time to discuss the corporate update and pipeline progress.

Use these tips for diversifying your investments in penny stocks The post How to Diversify Your Penny Stock Investments  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

High volume penny stocks to watch right now. The post Penny Stocks To Buy?

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, will present on January 12, 2023 at 7:30 a.m. Pacific time at the 41st Annual J.P. Morgan Healthcare Conference.

Surrozen, Inc. (SRZN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Surrozen to provide a business update including discussion of pipeline advancements Surrozen to provide a business update including discussion of pipeline advancements